This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers. This story matters for Finance & Markets readers tracking expo. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. ExpoNews curates and briefs the finance & markets stories that matter. Our editorial policy →